166 related articles for article (PubMed ID: 32318933)
1. Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare.
Gillette M; Taylor A; Butulija D; Kadiyala H; Jneid H
Cardiovasc Drugs Ther; 2020 Aug; 34(4):579-584. PubMed ID: 32318933
[TBL] [Abstract][Full Text] [Related]
2. Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities.
Charoo NA; Ali AA; Buha SK; Rahman Z
AAPS PharmSciTech; 2019 Apr; 20(5):166. PubMed ID: 30989447
[TBL] [Abstract][Full Text] [Related]
3. Abrupt Increase in Reporting of Neoplasms Associated with Valsartan After Medication Recall.
Al-Kindi SG; Oliveira GH
Circ Cardiovasc Qual Outcomes; 2019 Jul; 12(7):e005536. PubMed ID: 31266370
[No Abstract] [Full Text] [Related]
4. Nitrosamine Impurities in Angiotensin Receptor Blockers.
Shephard EA; Nawarskas JJ
Cardiol Rev; 2020; 28(5):262-265. PubMed ID: 32467427
[TBL] [Abstract][Full Text] [Related]
5. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
Bharate SS
J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
[TBL] [Abstract][Full Text] [Related]
6. A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023.
Patel R; Vhora A; Jain D; Patel R; Khunt D; Patel R; Dyawanapelly S; Junnuthula V
Drug Discov Today; 2024 Jun; 29(6):103993. PubMed ID: 38670257
[TBL] [Abstract][Full Text] [Related]
7. Neoplasm Reports in Food and Drug Administration Adverse Event Reporting System Following Angiotensin Receptor Blocker Recalls.
Cohen Sedgh R; Moon J; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2021 Aug; 14(8):e007476. PubMed ID: 34380327
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of FDA drug recalls: A 30-month analysis.
Hall K; Stewart T; Chang J; Freeman MK
Am J Health Syst Pharm; 2016 Feb; 73(4):235-40. PubMed ID: 26843501
[TBL] [Abstract][Full Text] [Related]
9. Hypertension Hot Potato - Anatomy of the Angiotensin-Receptor Blocker Recalls.
Byrd JB; Chertow GM; Bhalla V
N Engl J Med; 2019 Apr; 380(17):1589-1591. PubMed ID: 30865819
[No Abstract] [Full Text] [Related]
10. Moulds associated with contaminated ocular and injectable drugs: FDA recalls, epidemiology considerations, drug shortages, and aseptic processing.
Ahearn DG; Stulting RD
Med Mycol; 2018 Jun; 56(4):389-394. PubMed ID: 29420758
[TBL] [Abstract][Full Text] [Related]
11. Low quality of some generic cardiovascular medicinal products represents a matter for growing concern.
Tamargo J; Rosano G
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):176-187. PubMed ID: 31501855
[TBL] [Abstract][Full Text] [Related]
12. A four-year assessment of the characteristics of Rwandan FDA drug recalls.
Bahizi M; Nyirimigabo E; Ntirenganya L; Umuhoza MI; Habyalimana V; Bikorimana G; Ukwishaka J
BMC Public Health; 2024 Jul; 24(1):1784. PubMed ID: 38965502
[TBL] [Abstract][Full Text] [Related]
13. A QRM Discussion of Microbial Contamination of Non-sterile Drug Products, Using FDA and EMA Warning Letters Recorded between 2008 and 2016.
Santos AMC; Doria MS; Meirinhos-Soares L; Almeida AJ; Menezes JC
PDA J Pharm Sci Technol; 2018; 72(1):62-72. PubMed ID: 29242394
[TBL] [Abstract][Full Text] [Related]
14. Reflections on FDA Draft Guidance for Products Containing Nanomaterials: Is the Abbreviated New Drug Application (ANDA) a Suitable Pathway for Nanomedicines?
Emily M; Ioanna N; Scott B; Beat F
AAPS J; 2018 Aug; 20(5):92. PubMed ID: 30128758
[TBL] [Abstract][Full Text] [Related]
15. Quality of medicines in Canada: a retrospective review of risk communication documents (2005-2013).
Almuzaini T; Sammons H; Choonara I
BMJ Open; 2014 Oct; 4(10):e006088. PubMed ID: 25361839
[TBL] [Abstract][Full Text] [Related]
16. Categorization and comparisons of drug recalls for manufacturers and compounders.
Mattingly AN; Mattingly TJ; Nguyen Phan AL; Negash K
J Am Pharm Assoc (2003); 2022; 62(4):1344-1350. PubMed ID: 35422393
[TBL] [Abstract][Full Text] [Related]
17. Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health.
Ronquillo JG; Zuckerman DM
Milbank Q; 2017 Sep; 95(3):535-553. PubMed ID: 28895231
[TBL] [Abstract][Full Text] [Related]
18. Drug and medical device product failures and the stability of the pharmaceutical supply chain.
Livingston AN; Mattingly TJ
J Am Pharm Assoc (2003); 2021; 61(1):e119-e122. PubMed ID: 32753251
[TBL] [Abstract][Full Text] [Related]
19. FDA pharmaceutical quality oversight.
Yu LX; Woodcock J
Int J Pharm; 2015 Aug; 491(1-2):2-7. PubMed ID: 26027494
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of FDA safety-related drug label changes in 2010.
Lester J; Neyarapally GA; Lipowski E; Graham CF; Hall M; Dal Pan G
Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):302-5. PubMed ID: 23280652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
